- Oberland pours up to $400M into MeiraGTx eye gene therapies<figure><div><img src="https://imgproxy.divecdn.com/nnTWCzHBd9_O2uNBVPF6xmxcO0M-nRFDpca5z-2Xchs/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDMwNzQzODA0LmpwZ…BioPharma Dive · 18d ago↗ source
- Kailera says obesity pill succeeds in late-stage trial in China<figure><div><img src="https://imgproxy.divecdn.com/sHvIDEWnHWODDKUtbWbg7nZxoWKQNqB4C54nc9z4iH4/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTc4ODI5MzYyLmpwZ…BioPharma Dive · 18d ago↗ source
- Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filingCompass Pathways said Tuesday that patients in the second of its two pivotal psilocybin trials maintained their response to treatment for at least six months, keeping the company on track to comple…